GLUT5 is significantly upregulated in tumors from patients with the colon, lung, and breast adenocarcinoma, acute myeloid leukemia, ovarian carcinoma, and glioma where it contributes to malignancy and poor survival [16, 21, 23, 25–27]. The gene discussed is SLC2A5; the disease is acute myeloid leukemia.